Novartis ($NVS) was last year's biggest R&D spender in the pharma industry. Now, the company is warning U.K. officials that, unless they change their ways, Novartis will be spending less and less of its research billions in that country. Report
| Tuesday April 28th | 11am ET / 8am PT | Sponsored by: Parexel
This webinar will summarize the core scientific concepts needed to develop a global observational study protocol that describes or evaluates a therapeutic treatment in patients under conditions of usual care, in terms of clinical, humanistic and economic outcomes for a variety of key stakeholders. Register Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!